News

Two PhD studentships at the University of Huddersfield (UK)

More
  1. Antidiabetics in United Kingdom: Evaluating prescription patterns, drug utilisation and health outcomes
  2. Availability, affordability and pricing of high cost medicines in United Kingdom

Link: https://www.findaphd.com/search/PhDDetails.aspx?CAID=3064

Contact Professor Zaheer Babar Z.Babar@hud.ac.uk

New price study of high-cost medicines between European Union Member States 2015 published

More

In October 2016, the Austrian Public Health Institute published a comparison of prices of 60 high-cost medicines in Austria and the other Member States of the EU.

Key findings: The analysis showed that in comparison to other European countries Austrian prices of the surveyed medicines used in hospitals are higher than those of the selected out-patient medicines. A second key finding was that the Austrian pharmacy retail prices of surveyed medicines rank comparably higher in EU comparison than Austrian ex-factory prices or pharmacy purchasing prices. This suggests a possible need for action for Austrian policy-makers to optimize the pharmaceutical pricing system with particular attention on the areas of medicines used in hospitals (with no price regulation) and to pharmacy remuneration.

The full study (in German with an English Executive Summary) is available at: http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/GOeG_Preisstudie2015_Publikation%200-Fehler.pdf

A brief report in English is available at: http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/GOeG_Preisstudie2015_Kurzbericht_EN.%200-Fehler.pdf

New article on prices, costs, and affordability of new medicines for Hepatitis C in 30 countries published

More

A new study published by World Health Organization (WHO) and our WHO Collaborating Centre in Vienna finds Sofosbuvir globally unaffordable.

More information here:

Link: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002032

New article on stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement published

More

In this new article the authors (staff of our WHO Collaborating Centre) analysed preferences of eight stakeholder groups (patients, consumers, competent authorities for pharmaceutical P & R, public payers, research-oriented industry, generic medicines industry, pharmacists, doctors) towards policy objectives and pharmaceutical pricing and reimbursement measures in accordance with their preferred objectives.

More information here:

Link: http://www.healthpolicyandtechnology.org/article/S2211-8837(16)30009-0/abstract